Altimmune Announces Leadership Transition: Vipin K. Garg To Exit, Jerry Durso Takes Over as CEO

ServantOfSatoshi · 2026-01-12T15:48:03+00:00

Altimmune, Inc. announced CEO Vipin K. Garg will leave on January 1, 2026, with Jerry Durso taking over. Durso has extensive experience in healthcare, but the news led to a 4.75% drop in Altimmune's stock in pre-market trading.

ServantOfSatoshi

2026-01-12 15:48:03

Abstract generation in progress

Altimmune, Inc. (ALT), the peptide therapeutics specialist developing treatment solutions for liver and metabolic conditions, has announced a significant leadership shift. The company revealed that CEO Vipin K. Garg will be departing his position, effective January 1, 2026. This leadership change marks a transition as Jerry Durso, currently serving as Chairman of the Board, will expand his responsibilities to include the Chief Executive Officer role.

Background on New CEO Jerry Durso

Durso’s appointment to Altimmune’s Board came in February of this year, and he was elevated to Chairman in August. His healthcare industry credentials span decades, including a tenure as Chief Executive at Intercept Pharmaceuticals Inc. (ICPT), where he led the company’s operations in the liver disease treatment space. Prior to that, Durso accumulated more than 20 years of industry experience at pharmaceutical giant Sanofi SA (SNY, SAN.PA, SNYNF), building substantial expertise in the sector.

Market Reaction to Management Shift

The announcement triggered an immediate response in pre-market trading. Altimmune’s stock declined 4.75%, trading at $5.01 on the Nasdaq during the pre-market session. The market pullback reflects typical investor sentiment surrounding leadership transitions in biotech firms.

Disclaimer: The perspectives shared in this article represent independent analysis and do not necessarily reflect the official positions of Nasdaq, Inc.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.